SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor ($OPEN) is trending due to excitement surrounding the appointment of a new CEO with compensation heavily tied to stock performance, drawing comparisons to a "founder mode" mentality. The community is discussing the potential for a short squeeze and the company's long-term prospects in the evolving real estate market, with some highlighting the attractiveness of the company to new investment. Overall, the company has made a strong and interesting move that has captured the attention of a large online community.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending following the announcement of volume shipments of its NVIDIA Blackwell Ultra solutions, which has sparked bullish sentiment. The community is actively discussing the potential impact on earnings and the possibility of a stock re-rating, while also considering the company's historical compliance issues. Investors are weighing the potential upside against the stock's volatility and past challenges.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is trending as investors discuss its recent earnings report, highlighting raised fiscal 2025 revenue and profit forecasts driven by strong demand and AI tools. The community is focused on the company's AI strategy, particularly the monetization of AI tools like Firefly, with some analysts raising price targets.  Despite positive sentiment, there are mixed opinions on whether the stock's price movement reflects the strength of the report, as well as concern for the potential for IV crush.

Armada Acquisition Corp. I operates as a blank check company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. The company was founded on November 5, 2020 and is headquartered in Philadelphia, PA.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to a recent surge in price and buzz around its AI-powered visual search technology and upcoming earnings report. The community is discussing its potential for growth and comparing its valuation to AI peers, with some speculating about partnerships with major tech companies. A stop loss raid during after hours trading attracted more attention to the stock, leading to a quick recovery and renewed interest.

BGSF, Inc. engages in providing consulting, managed services, and professional workforce solutions. It operates through the Property Management and Professional segments. The Property Management segment offers office and maintenance talent in 38 states and D.C. to property management companies responsible for the apartment communities’ and commercial buildings’ day-to-day operations. The Professional segment is involved with specialized talent and business consultants for information technology, managed services, finance, accounting, legal and human resource. The company was founded on August 27, 2007, and is headquartered in Plano, TX.

BGSF Inc

BGSF is trending due to a declared special cash dividend of $2.00 per share, leading to discussions around dividend capture strategies and potential upside. Community members are comparing it to similar dividend plays like $SOGP, while assessing the potential for a short squeeze given the company's float. The dividend follows a divestiture, with investors now evaluating the company's capital allocation strategy.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

The $DOG memecoin on Bitcoin is trending, with the community highlighting its fair distribution, lack of insiders, and strong community as key differentiators. Many believe $DOG has the potential to outperform other meme coins and even "flip" Dogecoin due to its association with Bitcoin and its unique launch. Discussions also focus on its organic growth, strong community, and potential for listings on major exchanges.

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Addex Therapeutics Ltd - ADR

Addex Therapeutics ($ADXN) is trending due to a significant surge in price and volume, sparking discussions about a potential short squeeze. Community members are actively speculating on the reasons behind the sudden movement, with some attributing it to its low float and others pointing to a potential crypto treasury shift. Traders are closely watching key price levels, debating whether to jump in or wait for a pullback.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as traders anticipate the launch of the first U.S. Dogecoin ETF, with the community actively discussing potential price targets and accumulation strategies. The launch has stirred bullish sentiment, reflected in volume spikes and rising open interest in futures, as many believe this could signal increasing mainstream adoption and new investment flows into DOGE. Some traders are also closely watching technical indicators like RSI and key resistance levels for breakout potential.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation around a potential acquisition bid from Paramount Skydance, with the rumor driving significant trading volume and a jump in share price. The community is actively discussing the possible terms of a deal and the potential for a bidding war, with some believing WBD's assets are undervalued. This news arrives as WBD is planning to split into two separate publicly traded companies, adding another layer of complexity to the situation.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending as discussions revolve around its potential as a crypto/AI play and recent movements in Solana. Community members are highlighting the company's data center and crypto holdings, anticipating a positive Q3 earnings report. Bullish sentiment is fueled by comparisons to previous high-growth stocks and the expectation of further gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

Shares of SpringWorks Therapeutics Inc. ended over 9% higher on Thursday following a report that the company is inching closer to getting acquired by an established giant, triggering a jump in discussions among retail traders.During regular trading hours on Thursday, The Wall Street Journal reported that Merck KGaA is nearing a $3.5 billion deal to acquire SpringWorks, which specializes in rare diseases and cancer.The report, citing people familiar with the matter, noted that the German giant had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-jumps-ahead-of-q4-2024-report/ch5uuz0RwZ">confirmed</a> in February that it was in advanced talks for the buyout, and the two parties have now agreed on a price close to $47 per share.After the closing bell, Merck <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.eqs-news.com/news/ad-hoc/merck-kgaa-merck-confirms-late-stage-discussions-with-springworks-therapeutics-inc-on-potential-acquisition/b6bde507-964a-46d9-846d-9d15390345d9_en">confirmed</a> the report, saying the two parties were discussing a deal at around $47 per share. However, it added that they had neither made any final decision nor entered into a legally binding agreement.On Stocktwits, sentiment for SpringWorks jumped into the 'extremely bullish' zone, accompanied by a 657% spike in message volume.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/SWTX_sentiment_and_message_volume_as_of_April_24_png_712d46db30.webp" alt="SWTX sentiment and message volume as of April 24.png" width="1318" height="316"><figcaption>SWTX sentiment and message volume as of April 24. | source: Stocktwits</figcaption></figure>Several watchers appeared dissatisfied with the offer, indicating some alignment with the after-hours dip on Thursday."$47 is a joke, surely?" wrote one user, adding that Pfizer should throw its hat into the ring of prospective buyers.<stembedurl>https://stocktwits.com/monoksop/message/612643957</stembedurl>However, others expressed some relief."What I get, I get. Won't be super happy or anything, but I'll take the W and move on," said one watcher.<stembedurl>https://stocktwits.com/Son_of_Shango/message/612642003</stembedurl>SpringWorks has garnered interest from suitors thanks to its lead asset, Gomekli, which treats a rare genetic disorder that causes tumor growth in nerve tissue.The company's first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. It raked in $61.5 million in the fourth quarter of 2024.<a href="https://stocktwits.com/symbol/SWTX">SpringWorks' stock</a> has gained over 23% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A person examines financial data on a screen displaying a graph with upward and downward trends, using a pen to trace the line chart. | Representative Image: Getty Images

SpringWorks Therapeutics Retail Chatter Spikes As Germany’s Merck Confirms Late-Stage Talks For $3.5B Buyout

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.

Equity

After the closing bell, Merck said the two parties were discussing a deal at around $47 per share.


SpringWorks Therapeutics springs higher as Merck KGaA takeover said close

Investing.com -- Shares of  SpringWorks Therapeutics Inc  (NASDAQ:SWTX) surged higher Thursday afternoon on reports that a potential takeover of the company by Germany’s Merck KGaA (ETR:MRCG) is getting close.

Mineralys Therapeutics Inc. (123% jump in watchers)The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data from its Phase 3 and Phase 2 trials for lorundrostat in treating uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). Both trials met their primary efficacy endpoints, showing statistically significant blood pressure reductions.&nbsp;The company also announced a $250 million underwritten public offering to fund lorundrostat’s development and pre-commercialization efforts.Mineralys stock is up over 15% year-to-date (YTD).Tenaya Therapeutics Inc. (11% jump in watchers)Tenaya saw increased attention after reporting stronger-than-expected fourth-quarter earnings and highlighting upcoming clinical data readouts for its gene therapy programs targeting cardiomyopathies.&nbsp;CEO Faraz Ali noted continued progress in the TN-201 MyPEAK-1 and TN-401 RIDGE-1 trials.&nbsp;Tenaya’s stock remains down over 53% YTD.SpringWorks Therapeutics Inc. (10% jump in watchers)SpringWorks gained traction amid ongoing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-sees-biggest-weekly-biotech-jump-in-stocktwits-following/cheUZARRbb2">speculation</a> about a potential buyout by Merck KGaA. While Merck confirmed advanced merger discussions in its annual report, it stopped short of announcing a deal, leaving traders searching for clues. The company’s withdrawal from a Barclays healthcare conference further fueled speculation.&nbsp;SpringWorks stock is up more than 40% YTD.COSCIENS Biopharma Inc. (9% jump in watchers)COSCIENS initiated a Phase 2a clinical efficacy trial for its avenanthramides product, which is being explored for its anti-inflammatory properties. The trial, dubbed the AvenActive study, will assess safety and efficacy in two dosage arms.&nbsp;COSCIENS stock has gained over 20% YTD.Metagenomi Inc. (7% jump in watchers)Metagenomi published new research in Nature Communications on its novel CAST gene editing system, which enables precise, programmable integration of large gene cargoes. The technology could have major implications for treating genetic diseases like cystic fibrosis and Duchenne Muscular Dystrophy.&nbsp;Metagenomi stock is down more than 46% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week

Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.  

SpringWorks Therapeutics (SWTX) saw the biggest retail follower increase among biotech stocks last week on Stocktwits, even as its shares tumbled more than 14%, marking their worst weekly decline since mid-January.&nbsp;Despite the drop, retail sentiment flipped to 'bullish' from 'neutral,' driven by renewed speculation about German healthcare giant Merck KGaA (MKGAY) confirming details about a buyout.<figure class="image"><img style="aspect-ratio:1316/302;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_March_10_cba5133a09.png" alt="SWTX sentiment and message volume March 10.png" width="1316" height="302"><figcaption>SWTX sentiment and message volume March 10. | source: Stocktwits</figcaption></figure>According to The Fly, Barclays analyst Peter Lawson noted that some investors had anticipated confirmation of an acquisition from Merck's earnings report last week.&nbsp;However, Merck's annual report, published Thursday, only acknowledged that discussions about a potential merger were at an advanced stage but stated that there was no certainty a deal would be signed.&nbsp;The absence of a definitive announcement left traders analyzing the language for clues.Adding to speculation, SpringWorks canceled its planned appearance at Barclays' healthcare conference this week, continuing a pattern of event withdrawals following the FDA approval of its lead drug, Gomekli, for treating neurofibromatosis type 1 (NF1).&nbsp;The company had previously backed out of an earnings call and another public event, fueling investor theories that a significant corporate development was underway.&nbsp;Barclays maintained an 'Overweight' rating on SpringWorks, with a price target of $63. It sees limited regulatory risk to a potential Merck buyout.Retail traders on Stocktwits reacted strongly to these developments. Message volumes surged, and the company's follower count increased by 17.9%, the highest among all biotech stocks last week.&nbsp;Some investors speculated that an acquisition could be announced this week, with one suggesting a potential offer price of $120 per share — a 140% premium to SpringWorks' last closing price.&nbsp;<stembedurl>https://stocktwits.com/Aombeus/message/607327621</stembedurl>Another pointed to Merck not disclosing a termination of negotiations, which German law would have allegedly required if talks had ended, and reaffirmed their belief in SpringWorks' leadership.<stembedurl>https://stocktwits.com/TheGunnerAB/message/607292647</stembedurl>According to Koyfin, short interest in SpringWorks has declined from 15.7% at the start of the year to 12.2% last week, suggesting that bearish bets against the stock have been easing.&nbsp;The company's shares currently trade at a 47% discount to the average analyst price target of $72.88. Five of the eight analysts covering SpringWorks have a ‘Buy’rating, while three rate it a ‘Strong Buy,’ according to Koyfin.Despite last week's sharp decline, SpringWorks remains up more than 36% year-to-date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

SpringWorks Therapeutics Leads Biotech Pack In Weekly Retail Follower Surge: What's Fueling Interest?

Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.

SpringWorks Therapeutics Inc. (SWTX) shares surged more than 10% in Wednesday’s after-hours, signaling strong investor optimism ahead of its quarterly earnings report due after the next session.The biopharmaceutical company, focused on treatments for rare diseases and cancer, is expected to report a narrowing of fourth-quarter (Q4) adjusted losses to $0.71 per share from $1.44 a year earlier.&nbsp;Meanwhile, revenue is projected to soar to $57.16 million from $5.4 million.On Stocktwits, sentiment remained firmly bullish, though message volumes dipped slightly.The stock’s retail following grew over 2% in the past week and more than 26% in the past month.Users noted that after-hours trading volumes spiked well above the daily average, signaling heightened interest.<stembedurl>https://stocktwits.com/patten1962/message/604919223</stembedurl>One trader posted: “Yet another sleepless night ahead. I hope this is the last, and we can all celebrate.”<stembedurl>https://stocktwits.com/StrangerTrades/message/604917416</stembedurl>Recent investor enthusiasm has been fueled by&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/swtx-stock-soars-on-acquisition-buzz/ch5EgKYRtu">reports</a> that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks. While no official confirmation has been made, there are hopes that a potential deal could be signed in the coming weeks.Last week, BofA Securities raised its price target on SWTX to $87 from $65, maintaining a Buy rating. The research firm cited FDA approval for SpringWorks’ lead asset, Gomekli, as a key growth driver.Gomekli, a MEK inhibitor, treats neurofibromatosis type 1 (NF1), a rare genetic disorder that causes tumor growth in nerve tissue.In addition, SpringWorks’ first FDA-approved drug, Ogsiveo, is already available in the U.S. for adult desmoid tumor patients requiring systemic treatment. Last month, the company pre-announced Q4 U.S. Ogsiveo sales of $61.5 million.Despite the bullish momentum, short interest on SpringWorks stock climbed from 15.7% at the start of the year to 19.4% last week, according to Koyfin data.Still, SWTX shares have surged over 53% year-to-date, far outpacing the S&amp;P 500’s 4.7% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

SpringWorks Therapeutics Gains Retail Interest Ahead Of Q4 Earnings – What Investors Expect

Recent investor enthusiasm has been fueled by reports that German healthcare giant Merck KGaA is in advanced talks to acquire SpringWorks.

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over

SpringWorks Therapeutics and Jewelry Designer Jennifer Fisher Team Up to Encourage People with Desmoid Tumors to Take Action Before Their Tumor Takes Over SpringWorks Therapeutics and Jewelry...

Springworks Therapeutics shares surged over 36% Monday, reaching levels last seen in mid-April 2022, as buyout speculation drove heavy trading.&nbsp;The stock is on track for its best day on record following a Reuters report that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company, according to people familiar with the matter.&nbsp;If discussions are successful, a deal could be signed in the coming weeks, though neither Springworks nor Merck have commented on the report yet.Springworks is a commercial-stage biopharmaceutical company developing treatments for severe rare diseases and cancer.&nbsp;Ogsiveo, the company's first FDA-approved therapy, is used in the U.S. to treat adult patients with progressing desmoid tumors who require systemic treatment.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/SWTX_sentiment_and_message_volume_Feb_10_3b1f0e47dd.png" alt="SWTX sentiment and message volume Feb 10.png" width="1318" height="324"><figcaption>SWTX sentiment and message volume Feb 10 as of 12:10 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, sentiment for Springworks was 'extremely bullish' as message volume spiked, pushing the stock into the list of top trending symbols by late Monday morning.&nbsp;Retail traders flooded the platform with congratulatory messages for long-term holders, though some warned that a sharp pullback could occur if official statements refute the buyout rumors.<stembedurl>https://stocktwits.com/flanker30/message/603597464</stembedurl><stembedurl>https://stocktwits.com/AngusMacbeth/message/603598578</stembedurl>Last month, Springworks pre-announced fourth-quarter U.S. Ogsiveo sales of $61.5 million, exceeding TD Cowen's $57.0 million estimate and consensus expectations of $59.8 million. The brokerage had suggested that a buyout could be on the horizon.Springworks stock has risen 16% over the past 12 months. According to Koyfin data, its short interest stood at 18.4% as of the last check.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Springworks Stock Soars To Nearly 3-Year High On Buyout Buzz, Retail Sentiment Rockets

Reuters reported that German healthcare and technology group Merck KGaA is in advanced talks to acquire the company.

Springworks surges as Germany's Merck KGaA said to be targeting takeover

Investing.com -- Shares of Springworks Therapeutics (NASDAQ:SWTX) surged over 37% on Monday following reports that Germany’s  Merck  (NSE:PROR) KGaA is in advanced talks to acquire the U.S. biotech company, according to Reuters.

SpringWorks Therapeutics Stock Gets A RS Rating Lift

SpringWorks Therapeutics Stock Gets A RS Rating Lift...

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.40	--	--	N/A
Q2 '25	-$0.51	--	--	N/A
Q1 '25	-$0.94	--	--	N/A
Q4 '24	-$0.71	-$1.04	-47.07%	MISSED
Q3 '24	-$0.75	-$0.72	4.47%	BEAT

SWTX
SpringWorks Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '25

Historical Earnings

Latest SWTX News

SWTX SpringWorks Therapeutics Inc